The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis

Bing-Syuan Zeng; Jiann-Jy Chen; Chih-Wei Hsu; Chao-Ming Hung; Bing-Yan Zeng; Mein-Woei Suen; Wei-Chieh Yang; Hung-Yu Wang; Yow-Ling Shiue; Kuan-Pin Su; Cheng-Ta Li; Chih-Sung Liang; Brendon Stubbs; Yen-Wen Chen; Wei-Te Lei; Tien-Yu Chen; Shih-Pin Hsu; Ping-Tao Tseng

doi:10.1016/j.cmi.2026.01.014

Key Points

No significant evidence of increased infection risk was found related to GLP-1 receptor agonist or SGLT2 inhibitor use.
The analysis included multiple studies, showcasing the overall safety profile of these medications.
Network meta-analysis was applied to synthesize data from various clinical trials effectively.
Findings suggest that prescribing GLP-1 receptor agonists or SGLT2 inhibitors does not elevate infection risk.

Implication

Network meta-analysis reveals no significant infection-related adverse events in GLP-1 and SGLT2 treatment, suggesting safety.

Abstract

This analysis identifies no significant evidence of infection-related adverse events related to GLP-1 receptor agonist or SGLT2 inhibitor prescription.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zeng et al. (2026) studied this question.

synapsesocial.com/papers/69a75aadc6e9836116a20cb8 https://doi.org/10.1016/j.cmi.2026.01.014

View Full Paper

Ask AI

Bookmark

Share

The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading